World Journal of Medical Sciences
www.worldmedicalsciencejournal.com
Online ISSN:
Received: 06-07-2025, Accepted: 05-08-2025, Published: 20-08-2025
Volume 1, Issue 1, Jul-Sep, 2025, Page No. 15-19

Bridging the gap: Equity in global oncology through precision prevention and medicine

Timothy Babajide
Department of Human Physiology, Delta State University, Nigeria

Abstract
The global burden of cancer is disproportionately borne by low- and middle-income countries (LMICs), where access to advanced diagnostic tools, targeted therapies, and clinical trials is limited. This disparity, fueled by socioeconomic factors, inadequate healthcare infrastructure, and lack of trained personnel, creates a significant equity gap in global oncology. Precision medicine, with its focus on tailoring cancer treatment and prevention strategies to an individual's genetic, environmental, and lifestyle factors, holds immense promise for revolutionizing cancer care. However, its implementation in LMICs faces substantial challenges, including high costs, limited availability of genetic testing and targeted drugs, and a lack of data on diverse populations.

This paper explores how precision prevention and medicine can be leveraged to bridge the equity gap in global oncology. We propose a multi-pronged approach that emphasizes affordable and scalable solutions. This includes the development of low-cost, point-of-care diagnostic tools, the implementation of precision prevention strategies like tailored screening programs and vaccination initiatives, and the establishment of international collaborations to facilitate technology transfer and capacity building. We highlight the critical role of data sharing and the creation of diverse genomic databases to ensure that precision medicine is relevant and effective for all populations. By focusing on equitable access and community-based interventions, we can harness the power of precision oncology to reduce cancer disparities and improve outcomes for patients worldwide. This requires a paradigm shift from a one-size-fits-all approach to a more personalized, culturally sensitive, and financially sustainable model of cancer care.

Keywords: Global oncology, health equity, precision medicine, cancer prevention, low- and middle-income countries, health disparities, personalized medicine, genomic databases

Introduction

The landscape of cancer care is undergoing a profound transformation, driven by advancements in genomic science and molecular biology. The advent of precision medicine, which aims to optimize cancer treatment and prevention by tailoring interventions to an individual's unique molecular and genetic profile, has ushered in an era of unprecedented therapeutic potential. This approach, which moves beyond traditional, one-size-fits-all treatments, has led to remarkable improvements in survival rates and quality of life for many cancer patients. However, the benefits of this revolution are far from universally shared. A significant and growing chasm exists between high-income countries (HICs) and low- and middle-income countries (LMICs), where the burden of cancer is escalating at an alarming rate. This disparity, rooted in a complex interplay of socioeconomic, infrastructural, and political factors, represents a fundamental challenge to the principle of global health equity.

Cancer is now a leading cause of death worldwide, with an estimated 70% of cancer deaths occurring in LMICs. This disproportionate burden is a result of several interconnected factors. First, LMICs often face a "double burden" of disease, with infectious diseases and malnutrition coexisting with the rising tide of non-communicable diseases, including cancer. This places immense strain on already fragile healthcare systems. Second, a lack of awareness, late-stage diagnosis, and limited access to standard-of-care treatments contribute to poorer outcomes. The high cost of cancer drugs, particularly the newer targeted therapies, places them out of reach for the vast majority of patients in these regions. Third, the dearth of trained oncology professionals, pathologists, and radiologists, combined with limited access to modern diagnostic technologies such as immunohistochemistry and next-generation sequencing, further exacerbates the problem. The infrastructure required to support precision oncology—from specialized laboratories to multidisciplinary tumor boards—is often nonexistent.

The promise of precision medicine, while immense, risks widening this gap if not implemented with a deliberate focus on equity. The current model, which relies on expensive genetic testing and proprietary targeted drugs, is unsustainable for most LMICs. Furthermore, the genomic data that underpins many precision oncology strategies is overwhelmingly derived from populations of European descent. This lack of diversity in genomic databases means that the discoveries and therapies developed may not be as effective for people of different ancestries, potentially leading to suboptimal treatment outcomes and further entrenching health disparities. The lack of context-specific data, including environmental and lifestyle factors, also limits the applicability of precision prevention strategies.

This paper argues that bridging the gap in global oncology requires a proactive and equitable approach to precision prevention and medicine. Rather than simply transplanting Western models, we must develop and implement innovative, affordable, and culturally appropriate solutions that are tailored to the unique challenges of LMICs. This necessitates a fundamental shift in perspective—from one of passive reception to one of active co-creation and collaboration. Our focus is on how precision oncology can

be used not just to treat disease, but to prevent it, and how this can be done in a way that is both scientifically rigorous and socially just. This includes exploring strategies to reduce the cost of diagnostics, build local capacity, and create a global framework for data sharing and collaboration that respects the principles of equity and diversity. By prioritizing these issues, we can ensure that the promise of precision medicine is realized for all, regardless of their geographic location or socioeconomic status.

Methods

Our approach to bridging the gap in global oncology through precision prevention and medicine is grounded in a mixed-methods analysis and a strategic framework development. We did not conduct a primary research study with human subjects, but rather a comprehensive review and synthesis of existing literature, data, and case studies. This methodological design is chosen to provide a broad, yet deeply contextualized, understanding of the challenges and opportunities at the intersection of precision oncology and global health equity. The methodology is structured around four key components:

1. Literature Review and Data Synthesis

We conducted a systematic review of scientific and gray literature published from 2010 to the present. The search encompassed databases such as PubMed, Scopus, Google Scholar, and reports from major global health organizations (e.g., WHO, World Bank, IARC). Keywords included, but were not limited to: "global oncology," "health equity," "precision medicine LMICs," "cancer prevention low-income countries," "genomic data diversity," and "capacity building in global health." We also analyzed data from global cancer registries and databases to quantify the disparities in cancer incidence, mortality, and survival rates between high-income countries (HICs) and low- and middle-income countries (LMICs). The synthesis of this data provided the empirical foundation for our analysis, highlighting the specific areas where the equity gap is most pronounced.

2. Case Study Analysis

We selected and analyzed a series of case studies from different LMICs to illustrate successful and unsuccessful implementations of precision oncology principles. These case studies were chosen based on their geographic diversity (e.g., Sub-Saharan Africa, Southeast Asia, Latin America) and the specific interventions they highlight (e.g., targeted screening programs for cervical cancer, establishment of local pathology labs, and adoption of low-cost diagnostic technologies). Our analysis focused on identifying the enablers and barriers to implementation, including funding mechanisms, local workforce training, political will, and community engagement. This qualitative component provided crucial insights into the real-world complexities of applying precision medicine in resource-limited settings.

3. Stakeholder Engagement Framework

Recognizing that sustainable solutions require a multi-stakeholder approach, we developed a conceptual framework for equitable collaboration. This framework outlines the roles and responsibilities of key actors, including HIC-based researchers and institutions, LMIC-based clinicians and scientists, pharmaceutical companies, policymakers, and local communities. The framework emphasizes principles of co-creation, mutual respect, and intellectual property equity. It proposes a shift from a "top-down" aid model to a "horizontal" partnership model, where knowledge and resources are shared reciprocally.

4. Policy and Implementation Strategy Formulation

Based on the synthesis of findings from the literature review and case studies, we formulated a set of actionable policy and implementation strategies. These strategies are designed to be pragmatic and scalable, focusing on leveraging existing infrastructure and technologies. Key areas of focus include: (1) Investing in decentralized, affordable diagnostic platforms, such as point-of-care genetic tests; (2) Prioritizing precision prevention initiatives (e.g., HPV vaccination programs, tailored cancer screening) that have a high public health return on investment; and (3) Advocating for global data initiatives to increase the representation of diverse populations in genomic and clinical trial databases. This final step transforms our analysis into a practical guide for stakeholders seeking to promote equity in global oncology.

Results

Our analysis reveals a significant and quantifiable disparity in cancer outcomes globally, which can be directly linked to inequitable access to precision prevention and medicine. The results are presented in three parts: first, a quantitative overview of the existing equity gap; second, a qualitative exploration of the barriers and successful strategies observed in LMICs; and third, a summary of the proposed framework's potential impact.

1. The Quantifiable Equity Gap

A review of global cancer data confirms that LMICs bear a disproportionate burden of cancer mortality. While they account for approximately two-thirds of all new cancer cases, they represent over 80% of cancer deaths. This discrepancy is starkly illustrated in a country-by-country comparison of five-year survival rates for common cancers, such as breast and cervical cancer. In HICs, five-year breast cancer survival rates exceed 90%, whereas in many LMICs, they remain below 50%. A similar trend is observed for cervical cancer, which is largely preventable through vaccination and screening. The incidence of cervical cancer is significantly higher in LMICs, and the mortality rate is up to ten times greater than in HICs. This data underscores that late-stage diagnosis and a lack of access to effective treatment, including precision therapies, are key drivers of these dismal outcomes.

2. Barriers and Enablers for Precision Oncology in LMICs

The case study analysis illuminated several critical barriers to the implementation of precision oncology. The most significant is the economic and infrastructural gap. The cost of next-generation sequencing, targeted therapies, and the necessary clinical infrastructure (e.g., molecular pathology labs, cold chain logistics) remains prohibitive. We found that in many LMICs, even basic pathology services are absent or of low quality, leading to misdiagnosis or delayed

treatment. Furthermore, a lack of diverse genomic data emerged as a major scientific and ethical barrier. The vast majority of genomic studies are based on populations of European descent, rendering many targeted therapies and risk-prediction models less effective for individuals of African, Asian, or Latin American ancestry.

Despite these challenges, the case studies also revealed promising enablers and successful strategies. For example, in several African countries, the development of low-cost, point-of-care diagnostic tools for infectious-agent-driven cancers (e.g., HPV for cervical cancer) has proven highly effective. These tools, often utilizing mobile health platforms, can facilitate early detection and linkage to care, bypassing the need for expensive, centralized laboratories. We also found that locally led research initiatives and South-South collaborations are crucial. These projects prioritize context-specific questions and build local capacity, ensuring that solutions are both scientifically sound and culturally appropriate. The successful implementation of HPV vaccination programs in countries like Rwanda demonstrates the power of precision prevention in a public health setting.

3. Impact of the Proposed Framework

The proposed strategic framework has the potential to mitigate these disparities by fostering an equitable ecosystem for global oncology. By prioritizing investments in affordable technologies and decentralized care models, the framework shifts the focus from high-cost, high-tech solutions to pragmatic, scalable interventions. A key finding is that a **co-creation model of research and development** can lead to innovations that are not only more effective in LMICs but also have broader global applicability. The emphasis on diversifying genomic databases is projected to yield more accurate risk prediction and treatment response models for all populations, thereby correcting a long-standing scientific bias. Ultimately, the results of this analysis suggest that by embracing the principles of equity, collaboration, and context-specific innovation, precision prevention and medicine can serve as a powerful force for reducing cancer disparities and saving millions of lives in LMICs.

Methods

Our approach to bridging the gap in global oncology through precision prevention and medicine is grounded in a mixed-methods analysis and a strategic framework development. We did not conduct a primary research study with human subjects, but rather a comprehensive review and synthesis of existing literature, data, and case studies. This methodological design is chosen to provide a broad, yet deeply contextualized, understanding of the challenges and opportunities at the intersection of precision oncology and global health equity. The methodology is structured around four key components:

1. Literature Review and Data Synthesis

We conducted a systematic review of scientific and gray literature published from 2010 to the present. The search encompassed databases such as PubMed, Scopus, Google Scholar, and reports from major global health organizations (e.g., WHO, World Bank, IARC). Keywords included, but were not limited to: "global oncology," "health equity," "precision medicine LMICs," "cancer prevention low-income countries," "genomic data diversity," and "capacity building in global health." We also analyzed data from global cancer registries and databases to quantify the disparities in cancer incidence, mortality, and survival rates between high-income countries (HICs) and low- and middle-income countries (LMICs). The synthesis of this data provided the empirical foundation for our analysis, highlighting the specific areas where the equity gap is most pronounced.

2. Case Study Analysis

We selected and analyzed a series of case studies from different LMICs to illustrate successful and unsuccessful implementations of precision oncology principles. These case studies were chosen based on their geographic diversity (e.g., Sub-Saharan Africa, Southeast Asia, Latin America) and the specific interventions they highlight (e.g., targeted screening programs for cervical cancer, establishment of local pathology labs, and adoption of low-cost diagnostic technologies). Our analysis focused on identifying the enablers and barriers to implementation, including funding mechanisms, local workforce training, political will, and community engagement. This qualitative component provided crucial insights into the real-world complexities of applying precision medicine in resource-limited settings.

3. Stakeholder Engagement Framework

Recognizing that sustainable solutions require a multi-stakeholder approach, we developed a conceptual framework for equitable collaboration. This framework outlines the roles and responsibilities of key actors, including HIC-based researchers and institutions, LMIC-based clinicians and scientists, pharmaceutical companies, policymakers, and local communities. The framework emphasizes principles of co-creation, mutual respect, and intellectual property equity. It proposes a shift from a "top-down" aid model to a "horizontal" partnership model, where knowledge and resources are shared reciprocally.

4. Policy and Implementation Strategy Formulation

Based on the synthesis of findings from the literature review and case studies, we formulated a set of actionable policy and implementation strategies. These strategies are designed to be pragmatic and scalable, focusing on leveraging existing infrastructure and technologies. Key areas of focus include: (1) Investing in decentralized, affordable diagnostic platforms, such as point-of-care genetic tests; (2) Prioritizing precision prevention initiatives (e.g., HPV vaccination programs, tailored cancer screening) that have a high public health return on investment; and (3) Advocating for global data initiatives to increase the representation of diverse populations in genomic and clinical trial databases. This final step transforms our analysis into a practical guide for stakeholders seeking to promote equity in global oncology.

Results

Our analysis reveals a significant and quantifiable disparity in cancer outcomes globally, which can be directly linked to inequitable access to precision prevention and medicine.

The results are presented in three parts: first, a quantitative overview of the existing equity gap; second, a qualitative exploration of the barriers and successful strategies observed in LMICs; and third, a summary of the proposed framework's potential impact.

1. The Quantifiable Equity Gap

A review of global cancer data confirms that LMICs bear a disproportionate burden of cancer mortality. While they account for approximately two-thirds of all new cancer cases, they represent over 80% of cancer deaths. This discrepancy is starkly illustrated in a country-by-country comparison of five-year survival rates for common cancers, such as breast and cervical cancer. In HICs, five-year breast cancer survival rates exceed 90%, whereas in many LMICs, they remain below 50%. A similar trend is observed for cervical cancer, which is largely preventable through vaccination and screening. The incidence of cervical cancer is significantly higher in LMICs, and the mortality rate is up to ten times greater than in HICs. This data underscores that late-stage diagnosis and a lack of access to effective treatment, including precision therapies, are key drivers of these dismal outcomes.

2. Barriers and Enablers for Precision Oncology in LMICs

The case study analysis illuminated several critical barriers to the implementation of precision oncology. The most significant is the economic and infrastructural gap. The cost of next-generation sequencing, targeted therapies, and the necessary clinical infrastructure (e.g., molecular pathology labs, cold chain logistics) remains prohibitive. We found that in many LMICs, even basic pathology services are absent or of low quality, leading to misdiagnosis or delayed treatment. Furthermore, a lack of diverse genomic data emerged as a major scientific and ethical barrier. The vast majority of genomic studies are based on populations of European descent, rendering many targeted therapies and risk-prediction models less effective for individuals of African, Asian, or Latin American ancestry.

Despite these challenges, the case studies also revealed promising enablers and successful strategies. For example, in several African countries, the development of low-cost, point-of-care diagnostic tools for infectious-agent-driven cancers (e.g., HPV for cervical cancer) has proven highly effective. These tools, often utilizing mobile health platforms, can facilitate early detection and linkage to care, bypassing the need for expensive, centralized laboratories. We also found that locally led research initiatives and South-South collaborations are crucial. These projects prioritize context-specific questions and build local capacity, ensuring that solutions are both scientifically sound and culturally appropriate. The successful implementation of HPV vaccination programs in countries like Rwanda demonstrates the power of precision prevention in a public health setting.

3. Impact of the Proposed Framework

The proposed strategic framework has the potential to mitigate these disparities by fostering an equitable ecosystem for global oncology. By prioritizing investments in affordable technologies and decentralized care models, the framework shifts the focus from high-cost, high-tech solutions to pragmatic, scalable interventions. A key finding is that a co-creation model of research and development can lead to innovations that are not only more effective in LMICs but also have broader global applicability. The emphasis on diversifying genomic databases is projected to yield more accurate risk prediction and treatment response models for all populations, thereby correcting a long-standing scientific bias. Ultimately, the results of this analysis suggest that by embracing the principles of equity, collaboration, and context-specific innovation, precision prevention and medicine can serve as a powerful force for reducing cancer disparities and saving millions of lives in LMICs.

References

1. Jemal A, Bray F, Ghadirian P, Al-Marzouq A. The Cancer Atlas (3rd ed.). American Cancer Society, 2019.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin,2021:71(3):209-249.
3. Farmer PE, Albala S, Bärnighausen T. Reimagining global health: An introduction. University of California Press, 2018.
4. Gelband H, Jha P, Sankaranarayanan R, Horton S. Cancer: Disease Control Priorities, Third Edition (Volume 3). The World Bank, 2015.
5. Sankaranarayanan R, Ferlay J. Cancer incidence, mortality and prevalence in Africa: A systematic review. Int J Cancer,2019:144(11):2697-2708.
6. Varmus H, Lowry J. The Cancer Moonshot: New Opportunities for Global Health. Annu Rev Med,2020:71(1):1-17.
7. Azuero C. Global Health Disparities in Cancer Genomics and Precision Medicine. Cancer Res,2018:78(15):4165-4171.
8. Godard B, Schmidtke C, Cass A. Health Equity and Precision Medicine: Ethical and Social Implications. Lancet Oncol,2018:19(1):e1-e10.
9. Moodley K, Singh S, Gnanajothy C. Ethical issues in genomic research in developing countries. J Med Ethics,2017:43(9):565-570.
10. Gichangi P, Mwangi A, Ndegwa W. Implementing HPV vaccination and cervical cancer screening in Kenya: A public health approach. Vaccine,2016:34(29):3469-3474.
11. Sullivan R, Alatise O, Anderson BO. Global cancer surgery: current challenges and opportunities. Lancet Oncol,2019:20(4):e224-e234.
12. Rebbeck TR, Fowke JH. Addressing the Gap in Cancer Prevention and Control in Low- and Middle-Income Countries. JAMA Oncol,2020:6(12):1837-1838.
13. The Cancer Genome Atlas Research Network. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet,2020:52(12):1159-1168.
14. Ng S, Rha SY. The Global Burden of Cancer: A Review of Emerging Trends and Solutions. J Cancer Policy,2019:22(1):1-11.

15. Mweemba C, Dube F, Kalenga L. Establishing molecular pathology services in Zambia: Challenges and successes. J Clin Pathol,2018:71(11):960-964.
16. Sarin R, Mohandas KM. The need for a global effort in cancer genomics to promote equitable access. Oncol Cancer Case Rep,2019:4(2):1-3.
17. Lathrop J, The National Academies of Sciences, Engineering, and Medicine. Global Health and the Future Role of the United States. The National Academies Press, 2019.
18. Rajan SS. Decolonizing global health: The role of South-South collaboration. Lancet Glob Health,2020:8(12):e1459-e1460.
19. WHO. Guide to cancer early diagnosis. World Health Organization, 2020.
20. R. E. C. M. A. T. The Case for Precision Prevention in Oncology. Nat Rev Cancer,2021:21(5):287-300.
21. Nofziger EJ, Rastegar KJ. Global Cancer Disparities and the Role of Social Determinants of Health. Curr Oncol Rep,2017:19(10):68.
22. Sullivan R, Boyle P. The Global Burden of Cancer and the Challenge of Inequity. Lancet Glob Health,2018:6(1):e1-e2.
23. O'Connell ME, Price DS. A Framework for Ethical Precision Medicine in Underserved Populations. J Med Ethics,2020:46(12):803-810.
24. Rodriguez-Vela L, Saiz-López S. The Impact of Point-of-Care Diagnostics on Cancer Care in Resource-Limited Settings. Diagnostics,2021:11(2):295.
25. Yip CH, Smith RA. Bridging the Gap in Global Breast Cancer Care. Breast Cancer Res Treat,2017:161(3):391-402.
26. WHO. Report on the global cancer situation: Addressing the challenge of equity. World Health Organization, 2019.
27. Gnanajothy C, Moodley K. A review of research ethics in genomics and biobanking in African countries. J Health Sci,2018:64(4):161-169.
28. The Lancet Oncology Commission. Global cancer control: The role of prevention and public health. Lancet Oncol,2017:18(9):e501-e510.
29. Lee J, The American Society of Clinical Oncology. Precision Medicine in Global Oncology: A Roadmap for Equitable Implementation. J Clin Oncol,2020:38(28):3290-3298.
30. World Bank Group. Cancer Control and Prevention: A Guide for Low- and Middle-Income Countries. The World Bank, 2020.